Barry A. Berkowitz
Vorstandsvorsitzender bei Bessor Pharma LLC
Profil
Barry A.
Berkowitz joined Cetek Corp.
on December 12, 2005 and currently serves as President and Chief Executive Officer.
Prior to joining Cetek, he was Founder and Chief Executive Officer of New Chemical Entities, Inc., ChemGenics Pharmaceuticals, Inc., and Magainin Pharmaceuticals, Inc. (now Genaera Corp.).
Previously, Dr. Berkowitz held various research and development executive positions at SmithKline & French (now GlaxoSmithKline Plc) and research positions at the Roche Institute of Molecular Biology.
He received a Bachelor of Science degree in Pharmacy from Northeastern University and a PhD.
in Pharmacology from the University of California, San Francisco.
Aktive Positionen von Barry A. Berkowitz
| Unternehmen | Position | Beginn |
|---|---|---|
| Bessor Pharma LLC | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Barry A. Berkowitz
| Unternehmen | Position | Ende |
|---|---|---|
Genaera Corp.
 Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Corporate Officer/Principal | 13.07.2009 |
| GSK PLC | Corporate Officer/Principal | - |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Präsident | - |
| ChemGenics Pharmaceuticals, Inc. | Präsident | - |
AMRI Bothell Research Center, Inc.
 AMRI Bothell Research Center, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Curia Global, Inc., AMRI Bothell Research Center, Inc. is a company that provides drug discovery and information services. The company is based in Framingham, MA. AMRI Bothell Research Center was acquired by Curia Global, Inc. on January 25, 2001 for $22.40 million. | Präsident | - |
Ausbildung von Barry A. Berkowitz
| Northeastern University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Health Technology |
| ChemGenics Pharmaceuticals, Inc. | Commercial Services |
Cetek Corp.
 Cetek Corp. Pharmaceuticals: MajorHealth Technology Cetek Corp. discovers and develops pharmaceuticals & drugs. It offers contract drug discovery and collaboration services. The company discovers novel therapeutics by using chemistry, biology, and engineering. Cetek was founded by Dallas E. Hughes in 1996 and is headquartered in Marlborough, MA. | Health Technology |
Faraday Pharmaceuticals, Inc. (Washington)
 Faraday Pharmaceuticals, Inc. (Washington) Drugstore ChainsRetail Trade Faraday Pharmaceuticals, Inc. develops small molecule drugs for the treatment of central nervous system disorders and cardiovascular diseases. The company was founded in 2001 and is headquartered in Seattle, WA. | Retail Trade |
AMRI Bothell Research Center, Inc.
AMRI Bothell Research Center, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Curia Global, Inc., AMRI Bothell Research Center, Inc. is a company that provides drug discovery and information services. The company is based in Framingham, MA. AMRI Bothell Research Center was acquired by Curia Global, Inc. on January 25, 2001 for $22.40 million. | Commercial Services |
| Bessor Pharma LLC |